Weekly Recap: $500M raise and VANQUISH—1/2 fully enrolled
Viking Therapeutics, Inc. (NASDAQ:VKTX) bolstered its balance sheet with about $500M from equity and $225M of convertible notes to advance VK2735 and VK3019, reporting fully enrolled Phase III subcutaneous VK2735 trials (VANQUISH—1/2) due in 2027 and strong maintenance dosing results preserving up…